Do SSRIs or antidepressants in general increase suicidality?

WPA Section on Pharmacopsychiatry: consensus statement
  • Hans-Jürgen Möller
  • David S. Baldwin
  • Guy Goodwin
  • Siegfried Kasper
  • Ahmed Okasha
  • Dan J. Stein
  • Rajiv Tandon
  • Marcio Versiani
  • the WPA Section on Pharmacopsychiatry
ORIGINAL PAPER

Abstract

In the past few years several papers have reported critically on the risk of suicidal thoughts and behaviour associated with antidepressants, primarily SSRIs. The risk-benefit ratio of antidepressant (AD) treatment has been questioned especially in children and adolescents. The critical publications led to warnings being issued by regulatory authorities such as the FDA, MHRA and EMEA and stimulated new research activity in this field. However, potential harmful effects of antidepressants on suicidality are difficult to investigate in empirical studies because these have several methodological limitations. Randomised controlled trials (RCTs) are the most reliable way to test the hypothesis that AD have such side effects. In addition to meta-analyses of RCTs, complementary research methods should be applied to obtain the most comprehensive information. We undertook a comprehensive review of publications related to the topics ADs, suicide, suicidality, suicidal behaviour and aggression. Based on this comprehensive review we conclude that ADs, including SSRIs, carry a small risk of inducing suicidal thoughts and suicide attempts, in age groups below 25 years, the risk reducing further at the age of about 30–40 years. This risk has to be balanced against the well-known beneficial effects of ADs on depressive and other symptoms (anxiety, panic, obsessive-compulsive symptoms), including suicidality and suicidal behaviour. According to the principles of good clinical practice, decision making should consider carefully the beneficial effects of AD treatment as well as potentially harmful effects and attempt to keep the potential risks of AD treatment to a minimum. It is the major problem facing efforts to identify the possible ‘suicidal effects’ of antidepressants.

Keywords

antidepressants suicidality suicidal behaviour suicide 

References

  1. 1.
    Angst J, Angst F, Gerber-Werder R, Gamma A (2005) Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years’ follow-up. Arch Suicide Res 9:279–300PubMedCrossRefGoogle Scholar
  2. 2.
    Balazs J, Benazzi F, Rihmer Z, Rihmer A, Akiskal KK, Akiskal HS (2006) The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord 91:133–138PubMedCrossRefGoogle Scholar
  3. 3.
    Baldwin D, Bullock T, Montgomery D, Montgomery S (1991) 5-HT reuptake inhibitors, tricyclic antidepressants and suicidal behaviour. Int Clin Psychopharmacol 6(Suppl 3):49–55PubMedGoogle Scholar
  4. 4.
    Baldwin D, Fineberg N, Montgomery S (1991) Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol 6:51–58PubMedGoogle Scholar
  5. 5.
    Bauer MS, Wisniewski SR, Marangell LB, Chessick CA, Allen MH, Dennehy EB, Miklowitz DJ, Thase ME, Sachs GS (2006) Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry 67:48–55PubMedCrossRefGoogle Scholar
  6. 6.
    Beasley CM, Jr., Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH, Jr., Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN (1991) Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Br Med J 303:685–692Google Scholar
  7. 7.
    Boseley S (2001) Suicide fear over anti-depressant. http://society.guardian.co.uk/print/0,,4218909-106543,00.html.Anonymous
  8. 8.
    Brent DA (2004) Antidepressants and pediatric depression—the risk of doing nothing. N Engl J Med 351:1598–1601PubMedCrossRefGoogle Scholar
  9. 9.
    Buckley NA, McManus PR (2002) Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 325:1332–1333PubMedCrossRefGoogle Scholar
  10. 10.
    Carlsten A, Waern M, Ekedahl A, Ranstam J (2001) Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf 10:525–530PubMedCrossRefGoogle Scholar
  11. 11.
    Cassidy S, Henry J (1987) Fatal toxicity of antidepressant drugs in overdose. Br Med J (Clin Res Ed) 295:1021–1024Google Scholar
  12. 12.
    Cheeta S, Schifano F, Oyefeso A, Webb L, Ghodse AH (2004) Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998–2000. Br J Psychiatry 184:41–47PubMedCrossRefGoogle Scholar
  13. 13.
    Conner KR, Hesselbrock VM, Schuckit MA, Hirsch JK, Knox KL, Meldrum S, Bucholz KK, Kramer J, Kuperman S, Preuss U et al (2006) Precontemplated and impulsive suicide attempts among individuals with alcohol dependence. J Stud Alcohol 67:95–101PubMedGoogle Scholar
  14. 14.
    Dasgupta K (1990) Additional case of suicidal ideation associated with fluoxetine. Am J Psychiatry 147:1570Google Scholar
  15. 15.
    Didham RC, McConnell DW, Blair HJ, Reith DM (2005) Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication. Br J Clin Pharmacol 60:519–525PubMedCrossRefGoogle Scholar
  16. 16.
    emea European Medicines Agency finalises review of antidepressants in children and adolescents (2005) http://www.emea.eu.int/pdfs/human/press/pr/12891805en.pdf.Anonymous
  17. 17.
    Farmer RD, Pinder RM (1989) Why do fatal overdose rates vary between antidepressants? Acta Psychiatr Scand Suppl 354:25–35PubMedCrossRefGoogle Scholar
  18. 18.
    Fazel S, Grann M, Goodwin GM (2006) Suicide trends in discharged patients with mood disorders: associations with selective serotonin uptake inhibitors and comorbid substance misuse. Int Clin Psychopharmacol 21:111–115PubMedCrossRefGoogle Scholar
  19. 19.
    Fazel S, Grann M, Ahlner J, Goodwin G (2007) Suicides by violent means in individuals taking SSRIs and other antidepressants: a postmortem study in Sweden, 1992–2004. J Clin Psychopharmacol 27:503–506PubMedCrossRefGoogle Scholar
  20. 20.
    FDA Public Health Advisory Suicidality in children and adolescents being treated with antidepressant medications (2004) www.fda.gov/cder/drug/antidepressants/SSRIPHA200410.htm.Anonymous
  21. 21.
    FDA Public Health Advisory Suicidality in children and adolescents being treated with antidepressant medications (2007) www.fda.gov/cder/drug/advisory/SSRI_SS200607.htm.Anonymous
  22. 22.
    Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B (2005) Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. Br Med J 330:396CrossRefGoogle Scholar
  23. 23.
    Feuerlein W (1971) Attempted suicide or parasuicidal action? Tendency of suicidal behavior. Nervenarzt 42:127–130PubMedGoogle Scholar
  24. 24.
    Fleischmann A, Bertolote JM, Belfer M, Beautrais A (2005) Completed suicide and psychiatric diagnoses in young people: a critical examination of the evidence. Am J Orthopsychiatry 75:676–683PubMedCrossRefGoogle Scholar
  25. 25.
    Frey R, Schreinzer D, Stimpfl T, Vycudilik W, Berzlanovich A, Kasper S (2000) Suicide by antidepressant intoxication identified at autopsy in Vienna from 1991–1997: the favourable consequences of the increasing use of SSRIs. Eur Neuropsychopharmacol 10:133–142PubMedCrossRefGoogle Scholar
  26. 26.
    Frey R, Schreinzer D, Stimpfl T, Vycudilik W, Berzlanovich A, Kasper S (2002) [Fatal poisonings with antidepressive drugs and neuroleptics. Analysis of a correlation with prescriptions in Vienna 1991 to 1997]. Nervenarzt 73:629–636PubMedCrossRefGoogle Scholar
  27. 27.
    Geddes JR, Cipriani A (2004) Selective serotonin reuptake inhibitors. BMJ 329:809–810PubMedCrossRefGoogle Scholar
  28. 28.
    Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653–661PubMedCrossRefGoogle Scholar
  29. 29.
    Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2005) The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 62:165–172PubMedCrossRefGoogle Scholar
  30. 30.
    Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2006) The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 163:1898–1904PubMedCrossRefGoogle Scholar
  31. 31.
    Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, Herings RM, Mann JJ (2007) Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 164:1356–1363PubMedCrossRefGoogle Scholar
  32. 32.
    Glaxo (2006) Smith Kline Paroxetine: Important safety information regarding the risk of suicidal behaviour. Letter to Healthcare Professionals (Europe). http://www.gsk.com/media/par_current_analysis.htm.Anonymous
  33. 33.
    Grimes DA, Schulz KF (2002) Bias and causal associations in observational research. Lancet 359:248–252PubMedCrossRefGoogle Scholar
  34. 34.
    Grunebaum MF, Ellis SP, Li S, Oquendo MA, Mann JJ (2004) Antidepressants and suicide risk in the United States, 1985–1999. J Clin Psychiatry 65:1456–1462PubMedCrossRefGoogle Scholar
  35. 35.
    Gunnell D, Ashby D (2004) Antidepressants and suicide: what is the balance of benefit and harm. BMJ 329:34–38PubMedCrossRefGoogle Scholar
  36. 36.
    Gunnell D, Middleton N, Whitley E, Dorling D, Frankel S (2003) Why are suicide rates rising in young men but falling in the elderly?—a time-series analysis of trends in England and Wales 1950–1998. Soc Sci Med 57:595–611PubMedCrossRefGoogle Scholar
  37. 37.
    Gunnell D, Saperia J, Ashby D (2005) Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. Br Med J 330:385CrossRefGoogle Scholar
  38. 38.
    Hall WD, Mant A, Mitchell PB, Rendle VA, Hickie IB, McManus P (2003) Association between antidepressant prescribing and suicide in Australia, 1991–2000: trend analysis. B Med J 326:1008CrossRefGoogle Scholar
  39. 39.
    Hammad T Review and evaluation of clinical data: Relationship between psychotropic drugs and pediatric suicidality (2004) www.fda.gov/OHRMS/DOCKETS/AC/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf.Anonymous
  40. 40.
    Hammad TA, Laughren T, Racoosin J (2006) Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63:332–339PubMedCrossRefGoogle Scholar
  41. 41.
    Hammad TA, Laughren TP, Racoosin JA (2006) Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 26:203–207PubMedCrossRefGoogle Scholar
  42. 42.
    Harris EC, Barraclough B (1997) Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 170:205–228PubMedGoogle Scholar
  43. 43.
    Harris EC, Barraclough B (1998) Excess mortality of mental disorder. Br J Psychiatry 173:11–53PubMedGoogle Scholar
  44. 44.
    Hawton K, Hall S, Simkin S, Bale L, Bond A, Codd S, Stewart A (2003) Deliberate self-harm in adolescents: a study of characteristics and trends in Oxford, 1990–2000. J Child Psychol Psychiatry 44:1191–1198PubMedCrossRefGoogle Scholar
  45. 45.
    Healy D (2000) Emergence of antidepressant induced suicidality. Prim Care Psychiatry 6:23–28CrossRefGoogle Scholar
  46. 46.
    Healy D (2004) Let them eat prozac: the unhealthy relationship between the pharmaceutical industry and depression. New York university press, New YorkGoogle Scholar
  47. 49.
    Healy D, Herxheimer A, Menkes DB (2006) Antidepressants and violence: problems at the interface of medicine and law. PLoS Med 3:e372PubMedCrossRefGoogle Scholar
  48. 47.
    Healy D, Whitaker C (2003) Antidepressants and suicide: risk-benefit conundrums. J Psychiatry Neurosci 28:331–337PubMedGoogle Scholar
  49. 48.
    Healy D, Langmaak C, Savage M (1999) Suicide in the course of the treatment of depression. J Psychopharmacol 13:94–99PubMedGoogle Scholar
  50. 50.
    Henry JA (1989) A fatal toxicity index for antidepressant poisoning. Acta Psychiatr Scand Suppl 354:37–45PubMedCrossRefGoogle Scholar
  51. 51.
    Henry JA (1997) Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Saf 16:374–390PubMedGoogle Scholar
  52. 52.
    Henry JA, Alexander CA, Sener EK (1995) Relative mortality from overdose of antidepressants. BMJ 310:221–224PubMedGoogle Scholar
  53. 53.
    Holtmann M, Bolte S, Poustka F (2005) Suicidality in depressive children and adolescents during treatment with selective serotonin reuptake inhibitors Review and meta-analysis of the available randomised, placebo controlled trials. Nervenarzt [Epub ahead of print]Google Scholar
  54. 54.
    Hoover CE (1990) Additional case of suicidal ideation associated with fluoxetine. Am J Psychiatry 147:1570–1571Google Scholar
  55. 55.
    Isacsson G (2000) Suicide prevention—a medical breakthrough? Acta Psychiatr Scand 102:113–117PubMedCrossRefGoogle Scholar
  56. 56.
    Isacsson G, Holmgren P, Ahlner J (2005) Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. Acta Psychiatr Scand 111:286–290PubMedCrossRefGoogle Scholar
  57. 57.
    Jick SS, Dean AD, Jick H (1995) Antidepressants and suicide. BMJ 310:215–218PubMedGoogle Scholar
  58. 58.
    Jick H, Kaye JA, Jick SS (2004) Antidepressants and the risk of suicidal behaviors. JAMA 292:338–343PubMedCrossRefGoogle Scholar
  59. 59.
    Juurlink DD, Mamdani MM, Kopp A, Redelmeier DA (2006) The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 163:813–821PubMedCrossRefGoogle Scholar
  60. 60.
    Kapur S, Mieczkowski T, Mann JJ (1992) Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 268:3441–3445PubMedCrossRefGoogle Scholar
  61. 61.
    Kasper S, Schindler S, Neumeister A (1996) Risk of suicide in depression and its implication for psychopharmacological treatment. Int Clin Psychopharmacol 11:71–79PubMedCrossRefGoogle Scholar
  62. 62.
    Kelly CB, Ansari T, Rafferty T, Stevenson M (2003) Antidepressant prescribing and suicide rate in Northern Ireland. Eur Psychiatry 18:325–328PubMedCrossRefGoogle Scholar
  63. 63.
    Kerr GW, McGuffie AC, Wilkie S (2001) Tricyclic antidepressant overdose: a review. Emerg Med J 18:236–241PubMedCrossRefGoogle Scholar
  64. 64.
    Khan A, Warner HA, Brown WA (2000) Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 57:311–317PubMedCrossRefGoogle Scholar
  65. 65.
    Khan A, Khan S, Kolts R, Brown WA (2003) Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 160:790–792PubMedCrossRefGoogle Scholar
  66. 66.
    King RA, Riddle MA, Chappell PB, Hardin MT, Anderson GM, Lombroso P, Scahill L (1991) Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 30:179–186PubMedGoogle Scholar
  67. 67.
    Kirsch I, Moore TJ, Scoboria A, Nicholls SS (2002) The emperor’s new drugs: an analysis of antidepressant medication data submitted to the US Food, Drug Administration. Prevention and Treatment. Article 23. Posted 15 Jul 2002. http://www.journals.apa.org/prevention/volume5/pre0050023a.html.5.Anonymous
  68. 68.
    Klein DF (2006) The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children. Neuropsychopharmacology 31:689–699PubMedCrossRefGoogle Scholar
  69. 69.
    Kreitman N (1977) Parasuicide. Wiley, LondonGoogle Scholar
  70. 70.
    Kreitman N, Philip AE, Greer S, Bagley CR (1969) Parasuicide. Br J Psychiatry 115:746–747PubMedGoogle Scholar
  71. 71.
    Kurz A, Möller HJ, Baindl G, Burk F, Torhorst A, Wachtler C, Lauter H (1987) Classification of parasuicide by cluster analysis. Types of suicidal behaviour, therapeutic and prognostic implications. Br J Psychiatry 150:520–525PubMedGoogle Scholar
  72. 72.
    Kurz A, Möller HJ, Torhorst A, Lauter H (1988) Validation of six risk scales for suicide attempters. In: Möller HJ, Schmidtke A, Welz R (eds) Current issues of suicidology. Springer, Berlin, pp 174–178Google Scholar
  73. 73.
    Lapierre YD (2003) Suicidality with selective serotonin reuptake inhibitors: Valid claim? J Psychiatry Neurosci 28:340–347PubMedGoogle Scholar
  74. 74.
    Laughren TP (2006) Memorandum: overview for December 13 meeting of Psychopharmacologic Drugs Advisory Committee (PDAC) http://www.fda.gov/OHRMS/DOCKETS/AC/06/briefing/2006-4272b1-01-FDA.pdf.Anonymous
  75. 75.
    Lejoyeux M, Leon E, Rouillon F (1994) Prevalence and risk factors of suicide and attempted suicide. Encephale 20:495–503PubMedGoogle Scholar
  76. 76.
    Leon AC, Keller MB, Warshaw MG, Mueller TI, Solomon DA, Coryell W, Endicott J (1999) Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects. Am J Psychiatry 156:195–201PubMedGoogle Scholar
  77. 77.
    Licinio J, Wong ML (2005) Depression, antidepressants and suicidality: a critical appraisal. Nat Rev Drug Discov 4:165–171PubMedCrossRefGoogle Scholar
  78. 78.
    Ludwid J, Marcotte DE (2005) Anti-Depressants, Suicide and Drug Regulation. J Policy Anal Manage 24:249–272CrossRefGoogle Scholar
  79. 79.
    Mackay FR, Dunn NR, Martin RM, Pearce GL, Freemantle SN, Mann RD (1999) Newer antidepressants: a comparison of tolerability in general practice. Br J Gen Pract 49:892–896PubMedGoogle Scholar
  80. 80.
    Mann JJ, Kapur S (1991) The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy. Arch Gen Psychiatry 48:1027–1033PubMedGoogle Scholar
  81. 81.
    Mann JJ, Emslie G, Baldessarini RJ, Beardslee W, Fawcett JA, Goodwin FK, Leon AC, Meltzer HY, Ryan ND, Shaffer D et al (2006) ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 31:473–492PubMedCrossRefGoogle Scholar
  82. 82.
    Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, Evans S, Gunnell D (2005) Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 330:389PubMedCrossRefGoogle Scholar
  83. 83.
    Masand P, Gupta S, Dewan M (1991) Suicidal ideation related to fluoxetine treatment. N Engl J Med 324:420PubMedGoogle Scholar
  84. 84.
    Mayer-Gross W, Slater E, Roth M (1960) Clinical psychiatry. Bailliere, Tindall and Cassell, LondonGoogle Scholar
  85. 85.
    McClure GM (2001) Suicide in children and adolescents in England and Wales 1970–1998. Br J Psychiatry 178:469–474PubMedCrossRefGoogle Scholar
  86. 86.
    MHRA (2003) Selective Serotonin Reuptake Inhibitors (SSRIs): overview of regulatory status and CSM advice relating to major depressive disorder in children and adolescents including a summary of available safety and efficacy data. http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE &useSecondary=true&ssDocName=CON019494&ssTarget NodeId=221.Anonymous
  87. 87.
    Milane MS, Suchard MA, Wong ML, Licinio J (2006) Modeling of the temporal patterns of fluoxetine prescriptions and suicide rates in the United States. PLoS Med 3:e190PubMedCrossRefGoogle Scholar
  88. 88.
    Miller RA (1990) Discussion of fluoxetine and suicidal tendencies. Am J Psychiatry 147:1571Google Scholar
  89. 89.
    Mines D, Hill D, Yu H, Novelli L (2005) Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf 14:367–372PubMedCrossRefGoogle Scholar
  90. 90.
    Möller HJ (1990) Suicide risk and treatment problems in patients who have attempted suicide. In: Lester D (ed) Current concepts of suicide. Charles Press, Philadelphia, pp 168–181Google Scholar
  91. 91.
    Möller HJ (1992) Antidepressants—do they decrease or increase suicidality? Pharmacopsychiatry 25:249–253PubMedGoogle Scholar
  92. 92.
    Möller HJ (1992) Antidepressants—do they decrease or increase suicidality? Pharmacopsychiatry 25:249–253PubMedGoogle Scholar
  93. 93.
    Möller HJ (1992) Attempted suicide: efficacy of different aftercare strategies. Int Clin Psychopharmacol 6(Suppl 6): 58–69PubMedCrossRefGoogle Scholar
  94. 94.
    Möller HJ (2003) Suicide, suicidality and suicide prevention in affective disorders. Acta Psychiatr Scand Suppl 108:73–80CrossRefGoogle Scholar
  95. 95.
    Möller HJ (2004) SSRIs: are the accusations justified? World J Biol Psychiatry 5:174–175PubMedCrossRefGoogle Scholar
  96. 96.
    Möller HJ (2006) Evidence for beneficial effects of antidepressants on suicidality in depressive patients: a systematic review. Eur Arch Psychiatr Clin Neurosci 256:329–343CrossRefGoogle Scholar
  97. 97.
    Möller HJ (2006) Is there evidence for negative effects of antidepressants on suicidality in depressive patients? A systematic review. Eur Arch Psychiatr Clin Neurosci 256: 476–496CrossRefGoogle Scholar
  98. 98.
    Möller HJ (2006) Pharmacological/clinical mechanisms by which antidepressants could theoretically induce suicidal ideations or behaviour (in preparation)Google Scholar
  99. 99.
    Moncrieff J, Kirsch I (2005) Efficacy of antidepressants in adults. BMJ 331:155–157PubMedCrossRefGoogle Scholar
  100. 100.
    Montgomery SA, Dunner DL, Dunbar GC (1995) Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 5:5–13PubMedCrossRefGoogle Scholar
  101. 101.
    Morgan O, Griffiths C, Baker A, Majeed A (2004) Fatal toxicity of antidepressants in England and Wales, 1993–2002. Health Stat Q 23:18–24Google Scholar
  102. 102.
    Nutt DJ (2003) Death and dependence: current controversies over the selective serotonin reuptake inhibitors. J Psychopharmacol 17:355–364PubMedCrossRefGoogle Scholar
  103. 103.
    Ohberg A, Lonnqvist J, Sarna S, Vuori E, Penttila A (1995) Trends and availability of suicide methods in Finland. Proposals for restrictive measures. Br J Psychiatry 166:35–43PubMedCrossRefGoogle Scholar
  104. 104.
    Olfson M, Marcus SC, Shaffer D (2006) Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. Arch Gen Psychiatry 63:865–872PubMedCrossRefGoogle Scholar
  105. 105.
    Olfson M, Shaffer D, Marcus SC, Greenberg T (2003) Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 60:978–982PubMedCrossRefGoogle Scholar
  106. 106.
    Pedersen AG (2005) Escitalopram and suicidality in adult depression and anxiety. Int Clin Psychopharmacol 20:139–143PubMedCrossRefGoogle Scholar
  107. 107.
    Posner K, Oquendo MA, Gould M, Stanley B, Davies M (2007) Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164:1035–1043PubMedCrossRefGoogle Scholar
  108. 108.
    Reseland S, Bray I, Gunnell D (2006) Relationship between antidepressant sales and secular trends in suicide rates in the Nordic countries. Br J Psychiatry 188:354–358PubMedCrossRefGoogle Scholar
  109. 109.
    Reynolds CF III, Dew MA, Pollock BG, Mulsant BH, Frank E, Miller MD, Houck PR, Mazumdar S, Butters MA, Stack JA et al (2006) Maintenance treatment of major depression in old age. N Engl J Med 354:1130–1138PubMedCrossRefGoogle Scholar
  110. 110.
    Rihmer Z (2001) Can better recognition and treatment of depression reduce suicide rates? A brief review. Eur Psychiatry 16:406–409PubMedCrossRefGoogle Scholar
  111. 111.
    Rihmer Z, Akiskal H (2006) Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord [Epub ahead of print]Google Scholar
  112. 112.
    Rothschild AJ, Locke CA (1991) Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 52:491–493PubMedGoogle Scholar
  113. 113.
    Rouillon F (1994) [Long-term care with antidepressants]. Encephale 20:291–293PubMedGoogle Scholar
  114. 114.
    Rouillon F, Lejoyeux M, Filteau MJ (1992) Unwanted effects of long-term treatment. In: Rouillon F, Montgomery S (eds) Long-term treatment of depression. Perspectives in psychiatry. John Wiley, Chichester, pp 81–111Google Scholar
  115. 115.
    Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E (2007) Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 334:242PubMedCrossRefGoogle Scholar
  116. 116.
    Rujescu D, Thalmeier A, Möller HJ, Bronisch T, Giegling I (2006) Molecular genetic findings in suicidal behavior: what is beyond the serotonergic system? Arch Suicide Res (in press)Google Scholar
  117. 117.
    Seemüller F, Riedel M, Obermeier M, Mundt C, Marneros A, Laux G, Bender W, Adli M, Heuser I, Zeiler J et al (2007) The controversial link between antidepressants and suicidality risks in adults: Do data from the German Depression Katamnesis study support the FDA decisions of suicide warnings for antidepressants? Eur Arch Psychiatry Clin Neurosci (in press)Google Scholar
  118. 118.
    Shah R, Uren Z, Baker A, Majeed A (2001) Deaths from antidepressants in England and Wales 1993–1997: analysis of a new national database. Psychol Med 31:1203–1210PubMedCrossRefGoogle Scholar
  119. 119.
    Simon GE, Savarino J, Operskalski B, Wang PS (2006) Suicide risk during antidepressant treatment. Am J Psychiatry 163:41–47PubMedCrossRefGoogle Scholar
  120. 120.
    Stone MB, Jones ML (2006) Clinical review: Relationship between antidepressant drugs, suicidality in adults. http://www.fda.gov/OHRMS/DOCKETS/AC/06/briefing/2006-4272b1-01-FDA.pdf.Anonymous
  121. 121.
    Storosum JG, van Zwieten BJ, van den BW, Gersons BP, Broekmans AW (2001) Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry 158:1271–1275PubMedCrossRefGoogle Scholar
  122. 122.
    Teicher MH, Glod C, Cole JO (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147:207–210PubMedGoogle Scholar
  123. 123.
    Teicher MH, Glod CA, Cole JO (1993) Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety 8:186–212PubMedCrossRefGoogle Scholar
  124. 124.
    Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J (2006) Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 63:1358–1367PubMedCrossRefGoogle Scholar
  125. 125.
    Tollefson GD (1990) Fluoxetine and suicidal ideation. Am J Psychiatry 147:1691–1693PubMedGoogle Scholar
  126. 126.
    Tollefson GD, Rampey AH Jr, Beasley CM Jr, Enas GG, Potvin JH (1994) Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol 14:163–169PubMedGoogle Scholar
  127. 127.
    Vaiva G, Vaiva G, Ducrocq F, Meyer P, Mathieu D, Philippe A, Libersa C, Goudemand M (2006) Effect of telephone contact on further suicide attempts in patients discharged from an emergency department: randomised controlled study. BMJ 332:1241–1245PubMedCrossRefGoogle Scholar
  128. 128.
    Verkes RJ, Van der Mast RC, Hengeveld MW, Tuyl JP, Zwinderman AH, Van Kempen GM (1998) Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry 155:543–547PubMedGoogle Scholar
  129. 129.
    Vitiello B, Swedo S (2004) Antidepressant medications in children. N Engl J Med 350:1489–1491PubMedCrossRefGoogle Scholar
  130. 130.
    Volz HP, Baghai TC, Möller HJ (2006) Drug treatment of depression in the 2000s—an overview of achievements in the last ten years and future possibilities (in preparation)Google Scholar
  131. 131.
    Vorstman J, Lahuis B, Buitelaar JK (2001) SSRIs associated with behavioral activation and suicidal ideation. J Am Acad Child Adolesc Psychiatry 40:1364–1365PubMedCrossRefGoogle Scholar
  132. 132.
    Warshaw MG, Keller MB (1996) The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders. J Clin Psychiatry 57:158–166PubMedGoogle Scholar
  133. 133.
    Whyte IM, Dawson AH, Buckley NA (2003) Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 96:369–374PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Hans-Jürgen Möller
    • 1
  • David S. Baldwin
    • 1
  • Guy Goodwin
    • 1
  • Siegfried Kasper
    • 1
  • Ahmed Okasha
    • 1
  • Dan J. Stein
    • 1
  • Rajiv Tandon
    • 1
  • Marcio Versiani
    • 1
  • the WPA Section on Pharmacopsychiatry
  1. 1.Department of PsychiatryLudwig-Maximilians-University MünchenMunichGermany

Personalised recommendations